Compare DexCom, Inc. (DXCM) vs IONQ Inc (IONQ) Price & Performance

DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.

The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.

IONQ trades at $44.82, up 5.38% with a bullish technical signal supported by moving averages. The quantum computing company reported explosive 287% revenue growth in Q2 2026 to $80.1 million and raised its full-year outlook, though it remains deeply unprofitable with a -553% net margin. Recent catalysts include a $28 million DARPA contract extension and strong analyst sentiment with a $73.33 consensus price target representing 64% upside potential.

While IONQ demonstrates exceptional revenue momentum and technological leadership in quantum computing, investors face substantial risk from persistent losses, high cash burn, and valuation multiples exceeding 60x sales. The stock offers significant growth potential but requires tolerance for volatility and a long-term horizon given the nascent stage of quantum commercialization.